Nephrology

Investigators examine how different supplementation impacts kidney function in patients with type 2 diabetes.

Investigators present data from the CREDENCE trial during AHA.

Taking a routine invasive approach had no impact on clinical outcomes or quality of life in patients with chronic kidney disease as well as stable ischemic heart disease.

With ARBs linked to a higher risk of suicide, investigators suggest treating diseases like hypertension, chronic kidney disease, heart failure, and diabetes with ACEIs instead.

The results of a new survey regarding quality of care for end stage renal disease patients raise questions about how to improve the quality of end-of-life care.

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.

The SGLT2 inhibitor from Janssen has shown significant benefit for reducing progression to end-stage kidney disease, as well as risk for major adverse cardiovascular events.

In an extensive review of 18 cohort studies, investigators connect dietary patterns with chronic kidney disease incidence rates.

How new dapagliflozin findings from ESC 2019 and HFSA 2019 shape our understanding of the SGLT-2 inhibitor's benefit.

The headline drug class has been quickly added to cardiologists' toolsets, amid more and more phase 3 data.

An analysis of CREDENCE, EMPA-REG, the CANVAS Program, and DECLARE-TIMI 58 found SGLT2 inhibitor use reduced dialysis, transplantation, or death due to kidney disease by 33%.

The CREDENCE study of canagliflozin in adults with chronic kidney disease and type 2 diabetes met its primary endpoint as well as cardiovascular endpoints.

The canagliflozin (Invokana) application seeks a new indication to treat chronic kidney disease in patients with type 2 diabetes.

Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.

Positive data collected from 2 phase 2 trials evaluating bardoxolone methyl in patients with chronic kidney disease (CKD) caused by Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) have been reported.

Positive data for the add-on therapy for patients with type 2 diabetes and chronic kidney disease will be presented at an upcoming medical meeting.

Dimerix shares update on DMX-200, a combination therapy of propagermanium and irbesartan for the treatment of focal segmental sclerosis in addition to chronic kidney disease.

Expert speaks on management of patients with diabetes and chronic kidney disease.

Treating systolic blood pressure of >120 mmHG reduces risk of acute decompensated heart failure.

An investigational regimen of glecaprevir and pibrentasvir has proven to perform well in patients with hepatitis C genotypes 1 to 6 without cirrhosis.

When patients with chronic kidney disease also have untreated hepatitis C, the prognosis is grim. The combination can lead to end-stage renal disease, a study found.

An investigational combination drug that targets all major genotypes of hepatitis C had a high success rate in a clinical trial of patients with severe chronic kidney disease, curing 98% of those who received 12 weeks of treatment.

Age-related macular degeneration (AMD) was 72% more likely to develop in end-stage renal disease patients than in control subjects and 74% more likely to develop in peritoneal dialysis patients than in hemodialysis patients.

Roughly 20% of people with rheumatoid arthritis (RA) also suffer from chronic kidney disease (CKD), though no clear explanation exists as to whether or not that is coincidental.

The approximately nine million patients with advanced chronic kidney disease, low vitamin D, and secondary hyperparathyroidism (SHPT) can be treated with the first drug to be approved for the indication.

Maternal health just got that much more important as new research finds obesity contributes to chronic kidney disease risk in children.

Vitamin D has shown to play an important role in those with multiple sclerosis, chronic obstructive pulmonary disease (COPD), and even depression; now it looks like the same can be said about those with stage 3 or 4 chronic kidney disease (CKD).

Despite a considerable gap between the number of patients who require a transplant and the number of organs available those patients fortunate enough to receive the lifesaving organs are seeing greater success from the procedure.

With hundreds of thousands of people in the United States undergoing dialysis the field of nephrology is working hard to keep these patients as healthy as possible in hopes of getting them to the point of kidney transplant.

There is no shortage of people in need of a kidney transplant but a considerable shortage in the number of organs available to these patients. Despite that health care professionals in nephrology are determined to provide their patients the highest quality of life possible in spite of these challenges.